|
End-of-day quote
Dhaka S.E.
09/09/2026
|
5-day change | 1st Jan Change | ||
| 151.10 BDT | +0.33% |
|
+3.00% | +47.99% |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
| Market Cap | 67.41B 549M 472M 445M 405M 758M 52.23B 761M 5.27B 2.04B 26.61B 2.06B 2.02B 84.3B | P/E 2026 * |
7.78x | P/E 2027 * | 7.07x |
|---|---|---|---|---|---|
| Enterprise Value | 67.41B 549M 472M 445M 405M 758M 52.23B 761M 5.27B 2.04B 26.61B 2.06B 2.02B 84.3B | EV / Sales 2026 * |
1.23x | EV / Sales 2027 * | 1.11x |
| Free-Float |
85.91% | Yield 2026 * |
3.98% | Yield 2027 * | 5.09% |
| 1 day | +0.33% | ||
| 1 week | +3.00% | ||
| Current month | +3.99% | ||
| 1 month | +3.64% | ||
| 3 months | +21.37% | ||
| 6 months | +36.62% | ||
| Current year | +47.99% |
| 1 week | 148.5 |  | 154.5 |
| 1 month | 141.1 | | 154.5 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 04/03/2024 |
| Director of Finance/CFO | 63 | 01/01/2003 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 19/06/2009 | |
| Director/Board Member | - | 01/02/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 01/01/1985 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.33% | +3.00% | +17.86% | +3.35% | 546M | |
| +0.03% | -3.09% | +49.77% | +88.77% | 1,002B | |
| -0.76% | -2.95% | +50.93% | +64.20% | 649B | |
| +0.86% | -4.13% | +19.24% | +68.35% | 440B | |
| -0.80% | +0.06% | +28.73% | +35.45% | 346B | |
| -0.13% | -14.74% | +9.13% | +26.71% | 263B | |
| -1.90% | -2.61% | -2.67% | +7.41% | 250B | |
| -0.48% | -11.65% | +39.75% | +49.50% | 213B | |
| -1.06% | -1.70% | -16.73% | -57.36% | 201B | |
| -0.68% | -2.65% | +25.82% | +89.06% | 182B | |
| Average | -0.35% | -1.99% | +22.18% | +37.54% | 354.42B | |
| Weighted average by Cap. | -0.16% | -2.39% | +31.83% | +55.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 446M 384M 361M 329M 616M 42.45B 619M 4.28B 1.66B 21.63B 1.68B 1.64B 68.51B | 60.95B 496M 427M 402M 366M 686M 47.23B 688M 4.77B 1.84B 24.06B 1.86B 1.82B 76.23B |
| Net income | 8.66B 70.54M 60.7M 57.15M 52.07M 97.43M 6.71B 97.82M 677M 262M 3.42B 265M 259M 10.83B | 9.52B 77.56M 66.74M 62.84M 57.26M 107M 7.38B 108M 745M 288M 3.76B 291M 285M 11.91B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/09/26 | BDT 151.10 | +0.33% | 644,350 |
| 08/09/26 | BDT 150.60 | +0.40% | 1,147,197 |
| 07/09/26 | BDT 150.00 | -0.53% | 1,036,142 |
| 06/09/26 | BDT 150.80 | -1.57% | 992,154 |
| 03/09/26 | BDT 153.20 | +3.51% | 1,814,667 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
